Remote Technology Improves Adherence Rates in Relapsing MS
The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.
IL-1RA Biomarker Predicts Disability in Multiple Sclerosis
The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.
Cladribine Personalized Dosing Well Tolerated and Efficacious in Multiple Sclerosis
Researchers found that 22 of 23 patients with elevated CSF NfL at baseline had normal levels at 2-year follow-up.
CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD
The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
MS Fatigue Unchanged by Long-Term Programs, Raising Questions About Its Progression
The authors noted that future studies evaluating the time course of fatigue in patients with multiple sclerosis are needed.
Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.
This Week on NeurologyLive — March 1, 2021
Here's what is coming soon to NeurologyLive.
Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS
The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.
CNM-Au8 Displays Positive Interim Results in Multiple Sclerosis
Clene Nanomedicine’s nanocatalyst agent CNM-Au8 displayed significant improvements in patients with EDSS scores of 2.0 or higher compared to those with EDSS scores of 1.5 or lower.
Early DMT Prescription in Radiologically Isolated Syndrome: Ilena George, MD
The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.
Increasing Prevalence of Early DMT Prescription in Radiologically Isolated Syndrome
Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.
MS Diagnosis Disclosure and Concealment Associated With Anxiety, Depression
Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.
Importance of Evaluating Real-World Populations in MS: Allitia DiBernardo, MD
The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.
Fingolimod Shows Potential to Reduce Retinal Neurodegeneration in Relapsing MS
The authors concluded that longitudinal optical coherence tomography measures may be sensitive to changes in cognitive function and may be useful for monitoring neuroprotective therapies.
Siponimod Improves Cognitive Processing Speed, Opioid Use for Migraine in Emergency Departments, Reduced Stroke Admissions During Pandemic
Neurology News Network for the week ending February 27, 2021.
Natalizumab Infusion Reports Strong Safety Profile, Rarely Causes Adverse Events in Relapsing MS
Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.
Social Activity Participation Impacted by Invisible Symptoms of MS
Data from a pair of posters suggest that cognition, fatigue, and depression all impact social activity limitations in people with MS, rather than walking impairment alone.
NeurologyLive Friday 5 — February 26, 2021
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.
Instrumented Postural Sway Test Differentiates Fallers From Non-Fallers in MS
Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.
Investigating TNFα Inhibition and CNS Demyelination: Spencer Hutto, MD
The fellow of autoimmune neurology at Massachusetts General Hospital discussed the analysis his team conducted to clarify the known associations.
New Studies Evaluating Anakinra and Tolebrutinib on Paramagnetic Rim Lesions in MS
The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.
Episode 30: Cognitive Behavioral Therapy for Insomnia
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Martin, PhD.
Frenkel Coordination Exercises Demonstrate Reliability, Fatigue Benefits in Multiple Sclerosis
The authors concluded that this approach may be applied in fatigue management treatment protocols, without increasing symptoms, in patients with multiple sclerosis.
Growing Multiple Sclerosis Treatment Knowledge: Luc Truyen, MD, PhD
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed the areas research has grown in MS and areas that still need more examination.
Sarepta’s Casimersen Approved for DMD Amenable to Exon 45 Skipping
The antisense oligonucleotide casimersen will be branded as Amondys 45 and is currently being assessed in the ESSENCE phase 3 clinical trial (NCT02500381).
Cladribine Demonstrates CD19+ B and CD4+ T Lymphocyte Impact Regardless of Age
The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.
Measuring MS Fatigue in a Real-World Setting: Allitia DiBernardo, MD
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
TNFαi-Associated CNS Demyelination Persists After Treatment Discontinuation
Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.
Tapping Into the Potential of Cell and Gene Therapy
Advancements in gene therapy approaches have opened the door for a glimpse into the future of care for a number of diseases.
Parkinson Disease Treatment Tavapadon Aims to Benefit From Unique Multitrial Designs
Tavapadon’s rare combination of efficacy and minimal adverse effects may indicate a step forward in the treatment of Parkinson disease.
